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DOI 10.1016/j.chembiol.2012.02.005On December 23, 2011, the National
Institutes of Health (NIH) expanded its
research body with the launch of its 27th
center, the National Center for Advancing
Translational Science (NCATS). Its
mission is to ‘‘.catalyze the generation
of innovation methods and technologies
that will enhance the development,
testing, and implementation of diagnos-
tics and therapeutics across a wide range
of human diseases and conditions.’’
On that day, NIH Director Francis
Collins wrote on the Feedback NIH
blog (http://feedback.nih.gov/ncats/
ncats_established):
‘‘.NCATS is coming at just the right
time—we have an abundance of scientificNCATS’s long-term effort is to re-engineer the process of
translational science within NIH to make the development of
diagnostics and therapeutics much more efficient.advances and new technologies, but
we are using old tools for many steps
in therapeutic development. The goal
of NCATS will be to develop new
ways of doing translational research
that the public and private research and
development communities can adopt.
Innovations that come out of NCATS
are intended to cut down the time or
expense needed to develop a new drug,
or allow us to predict which compounds
will work best and be safe earlier in
development.’’
In December, 2010, the NIH Scientific
Management Review Board (SMRB),
a group of senior scientists who look at-
the operations of the NIH and make
recommendations about organizational
changes, issued its ‘‘Report on Trans-
lational Medicine and Therapeutics’’
(http:/smrb.od.nih.gov/documents/reports/
TMAT_122010.pdf). ‘‘The bottom line was
that the report asked the NIH to look
more carefully in what we do in the area
of translational science and to consider
a reorganization that would result in theNIH having a bigger impact on the
process of translation—bringing discov-
eries made in basic science forward into
new diagnostics and medicines,’’ says
Thomas Insel, Director of the National
Institute of Mental Health (NIMH) and
Interim NCATS Director. ‘‘In short, it
asked us to find ways of doing transla-
tional science better at NIH.’’
NCATS’s long-term effort is to re-engi-
neer the process of translational science
within NIH to make the development of
diagnostics and therapeutics much more
efficient. ‘‘There are 26 other centers
and institutes at NIH and virtually every
one of them is committed to translational
research,’’ says Insel. ‘‘At the end of theday, we’d like to serve all of them and their
partners to make sure they all succeed in
their missions.’’
Insel sees NCATS as having a central
role in helping NIH advance fundamental
discoveries to develop tools, resources,
and innovations that will result in the
development of diagnostics and thera-
peutics. To do so, NCATS has the task
of figuring out how to re-engineer that
effort to avoid many of today’s bottle-
necks that slow down translational of
discoveries to applications.
Key Bottlenecks
Insel and other NCATS directors are
focusing on addressing a few top priori-
ties or areas of known bottlenecks.
‘‘Certainly, identifying therapeutic tar-
gets and validating them is a key area.to
be thinking [about].,’’ he says. Today’s
explosion of genomics-based information
is offering up details about potential
pathways in a variety of disease areas.
Finding and confirming new ways for
intervening in these pathways is the nextChemistry & Biology 19, February 24, 2012step in advancing these discoveries
towards a clinical use.
Along with advancing new biology,
NCATS hopes to weigh in on novel
chemistry development. Insel explains,
‘‘This means improving capabilities in
medicinal chemistry and drug design.’’
Once biology and chemistry meet, Insel
points out that there is a gaping problem
regarding preclinical toxicology testing.
‘‘We know that so many compounds fail
because of toxicity,’’ he explains. A major
problem is that animal research has not
been entirely predictive of the toxic effects
that surface in human testing, often after
years of time and money developing a
particular compound. ‘‘This is a major
problem in the biotechnology and pharma-
ceutical industries and we want to improve
predictive toxicologymethods,’’ Insel says.
NCATS will also take on the challenge
of findings new ways of developing reli-
able biomarkers in the areas of diagnos-
tics and in tracking clinical responses to
therapy.
One of Dr. Insel’s greatest interests is in
‘‘rescuing and repurposing’’ existing
compounds that now sit unused or un-
tested in the freezers of academicians
and private companies. If NCATS can
devise template agreements to allow this
to happen, it could enable external bodies
and companies to contribute dormant
compounds. Insel also explains that
NCATS might become the gateway for
academic investigators to learn about
what is available for study. ‘‘Those kinds
of things would be enormously helpful
for me within NIMH, and I imagine I would
not be alone among my fellow NIH direc-
tors,’’ Insel adds.
Contributions to Industry
After the SRMB report was issued, the
proposed NCATS governing body sought
the input of many potential stakeholders,
including those from biotechnology and
related industries as well as academic
investigators, to identify their key issues.
From industry, NCATS is taking on at
least three concerns. One is investigatingª2012 Elsevier Ltd All rights reserved 165
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Food and Drug Administration (FDA) to
ensure drug safety and efficacy. Industry
also wants NCATS to help develop better
predictive toxicology methods to improve
the odds of success in the drug develop-
ment process. ‘‘And we have been asked
to work on workforce training issues so
that doctoral and postdoctoral scientists
receive some of the fundamental skills of
clinical pharmacology required by those
hiring in the industrial setting,’’ adds Insel.
NCATS also hopes to aid in the in-
creasing demand for new diagnostics
and therapies for rare and neglected dis-
eases—an area of increasing interest
from public health advocates and as well
as those in private industry. To answer
this call, NCATS will be the new home of
the Therapeutics for Rare and Neglected
Diseases (TRND) program, which focuses
on not just finding new therapeutics but
also on re-engineering the entire process
for developing therapeutics for these
diseases.166 Chemistry & Biology 19, February 24, 201New Home for Existing Programs
Though NCATS is a new NIH center, it
will primarily be home to programs and
efforts that already operate elsewhere
within NIH. (A complete list of NCATS’s
components can be found on the NCATS
website.) ‘‘They have been reorganized
into this new center essentially to create
some new adjacencies and improve inter-
action,’’ says Insel.
The only new NCATS entity is the newly
funded Cures Acceleration Network
(CAN), set to launch with a modest $10
million budget. CAN is intended to
advance the development of ‘‘high need
cures,’’ particularly in areas that private
companies are unlikely to pursue.
The first priority on NCATS’s agenda
is to find a permanent director to guide
the center’s 250 person team. A portion
of this group will be devoted to grant
review and overseeing administration of
the center’s clinical translational science
awards (CTSA program) that fund
about 60 research sites across the2 ª2012 Elsevier Ltd All rights reservedcompany with grants totaling nearly
$500 million.
A sizable group of about 140 people
within NCATS will do hands-on intramural
research within NIH, including small-
molecule screening and drug develop-
ment for rare diseases. ‘‘However, most
of those projects are collaborative with
external scientists both in academia and
industry,’’ Insel explains. One example
includes the TRND team, which is working
with scientists at various external sites to
find new treatments for sickle cell anemia,
CLL, Neimann-Pick disease, and other
disease targets.
‘‘An effort like NCATS, which is funda-
mentally focused on innovation, is going
to serve both basic and more applied
translational science,’’ adds Insel. ‘‘What
we hope to do is blur or bridge the division
between the two for the benefit of all—it’s
a great opportunity.’’Alice McCarthy (alice@alicemccarthy.com) is a
science writer based in Gloucester, Massachusetts.
